Genome Pharmaceuticals Completes DM6.5 Million In Venture Financing | GenomeWeb

MUNICH--In what is claimed to be the largest amount of seed financing raised by a biotech company in Germany to date, Genome Pharmaceuticals, a functional genomics firm here, has completed a DM6.5 million seed round of venture capital financing led by BB Bioventures, Cambridge, Mass., with Techno Venture Management here as coinvestor. Genome has also applied for state and federal funding from the Bayerische Kapitalbeteiligungsgesellschaft and Technologie Beteiligungs gesellschaft der Deutschen Ausgleichsbank.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.